Overexpression of AMP-activated kinase sensitizes Sorafenib-resistant Hepatocellular cancer cells and decreases stem cell markers

Published: 29 May 2019 | Version 1 | DOI: 10.17632/b6kvr4bzxp.1
Contributor(s):

Description of this data

Data used to generate figures of the paper by Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I. “Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib” Mol Oncol. 2019 May;13(5):1311-1331. doi: 10.1002/1878-0261.12488.
In this study we demonstrate that the AMP-activated kinase AMPK reverse the Cancer Stem cell features of Hepatocellular CSC.

Experiment data files